Respiratory Medicine
Volume 104, Issue 9 , Pages 1237-1245 , September 2010

Choosing inhaler devices for people with asthma: Current knowledge and outstanding research needs

  • John Haughney

      Affiliations

    • Centre of Academic Primary Care, University of Aberdeen, Foresterhill Health Centre, Westburn Road, Aberdeen AB25 2AY, Scotland, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 (0)1224 554588; fax: +44 (0)1224 550683.
    • ,
  • David Price

      Affiliations

    • Centre of Academic Primary Care, University of Aberdeen, Foresterhill Health Centre, Westburn Road, Aberdeen AB25 2AY, Scotland, UK
    • ,
  • Neil C. Barnes

      Affiliations

    • Department of Respiratory Medicine, London Chest Hospital, Bonner Road, London E2 9JX UK
    • ,
  • J. Christian Virchow

      Affiliations

    • Universität Rostock, Zentrum für Innere Medizin, Abteilung für Pneumologie und internistische Intensivmedizin, Ernst-Heydemann-Straße 6, D-18057 Rostock, Germany
    • ,
  • Nicolas Roche

      Affiliations

    • Service de pneumologie et réanimation, Hôpital Hôtel Dieu, 1 Place du Parvis Notre Dame, 75004 Paris, France
    • ,
  • Henry Chrystyn

      Affiliations

    • School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire HD1 3DH, UK

Received 26 November 2009 ,Accepted 15 April 2010.

References 

  1. British Thoracic Society, Scottish Intercollegiate Guidelines Network . British guideline on the management of asthma. May 2008;http://www.sign.ac.uk/guidelines/fulltext/101/index.htmlrevised June 2009
  2. Global Initiative for Asthma (GINA) . Global strategy for asthma management and prevention. 2009;http://www.ginasthma.org[Updated 2009]
  3. Sestini P, Cappiello V, Aliani M, et al. Prescription bias and factors associated with improper use of inhalers. J Aerosol Med. 2006;19:127–136
  4. Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med. 2008;102:1681–1693
  5. Horne R, Price D, Cleland J, et al. Can asthma control be improved by understanding the patient’s perspective?. BMC Pulm Med. 2007;7:8
  6. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001;5:1–149
  7. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ. 2001;323:896–900
  8. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335–371
  9. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest. 2000;117:542–550
  10. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593–604
  11. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: An observational study in 3811 patients in primary care. J Aerosol Med. 2003;16:249–254
  12. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir Med. 2000;94:496–500
  13. Schulte M, Osseiran K, Betz R, et al. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv. 2008;21:321–328
  14. Hardwell A, Barber V, Hargadon T, Levy M. Technique training does not improve the ability of most patients to use pressurised Metered Dose Inhalers (pMDI). Prim Care Respir J. 2009;18:A1;Abstract
  15. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991;46:712–716
  16. Lahdensuo A, Muittari A. Bronchodilator effects of a fenoterol metered dose inhaler and fenoterol powder in asthmatics with poor inhaler technique. Eur J Respir Dis. 1986;68:332–335
  17. Lindgren S, Bake B, Larsson S. Clinical consequences of inadequate inhalation technique in asthma therapy. Eur J Respir Dis. 1987;70:93–98
  18. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002;19:246–251
  19. Khassawneh BY, Al-Ali MK, Alzoubi KH, et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care. 2008;53:324–328
  20. van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J. 1999;14:1034–1037
  21. Thomas M, Price D, Chrystyn H, Lloyd A, Williams AE, von Ziegenweidt J. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med. 2009;9:1
  22. Kemp L, Barnes N, Haughney J, Sims E, von Ziegenweidt J, Price D. The effectiveness of different inhaler types used in the “real-life” management of asthma (GPRD-REALITY). AAAAI Annual Meeting; 2009 13–17 March; Washington DC. Abstract.
  23. Kemp L, Price D, Sims E, Dorinsky P, von Ziegenweidt J. ‘Real-Life’ Effectiveness of Qvar, Beclomethasone and Fluticasone. J Allergy Clin Immunol. 2009;123:6;Abstract
  24. Price D, Thomas M, Mitchell G, Niziol C, Featherstone R. Improvement of asthma control with a breath-actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device. Respir Med. 2003;97:12–19
  25. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122:510–516
  26. Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis. 1985;132:541–547
  27. Mak JC, Barnes PJ. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis. 1990;141:1559–1568
  28. Jeffery PK. Structural, immunologic, and neural elements of the normal human airway wall. In:  Busse W,  Holgate ST editor. Asthma and rhinitis. Oxford: Blackwell Scientific Publications; 1995;p. 80–106
  29. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol. 1997;100:44–51
  30. Tulic MK, Hamid Q. New insights into the pathophysiology of the small airways in asthma. Clin Chest Med. 2006;27:41–52
  31. Chrystyn H. Anatomy and physiology in delivery: can we define our targets?. Allergy. 1999;54(Suppl. 49):82–87
  32. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497–1504
  33. Al-Showair RA, Pearson SB, Chrystyn H. The potential of a 2Tone Trainer to help patients use their metered-dose inhalers. Chest. 2007;131:1776–1782
  34. Juniper EF, Price DB, Stampone PA, Creemers JP, Mol SJ, Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest. 2002;121:1824–1832
  35. Martin RJ. Exploring the distal lung: new direction in asthma. Isr Med Assoc J. 2008;10:846–849
  36. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346–1353
  37. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104:1215–1222
  38. Self TH, Pinner NA, Sowell RS, Headley AS. Does it really matter what volume to exhale before using asthma inhalation devices?. J Asthma. 2009;46:212–216
  39. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl. 1982;119:57–65
  40. Pauwels R, Newman S, Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J. 1997;10:2127–2138
  41. Tomlinson HS, Corlett SA, Allen MB, Chrystyn H. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge. Br J Clin Pharmacol. 2005;60:605–610
  42. Hesselink AE, Penninx BW, Wijnhoven HA, Kriegsman DM, van Eijk JT. Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scand J Prim Health Care. 2001;19:255–260
  43. Nimmo CJ, Chen DN, Martinusen SM, Ustad TL, Ostrow DN. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Ann Pharmacother. 1993;27:922–927
  44. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers–implications for in vitro testing. J Aerosol Med. 1993;6:99–110
  45. Chrystyn H, Price D. What you need to know about inhalers and how to use them. Prescriber. 2009;20(12):47–52
  46. Broeders ME, Molema J, Vermue NA, Folgering HT. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J. 2001;18:780–783
  47. Weuthen T, Roeder S, Brand P, Mullinger B, Scheuch G. In vitro testing of two formoterol dry powder inhalers at different flow rates. J Aerosol Med. 2002;15:297–303
  48. Palander A, Mattila T, Karhu M, Muttonen E. In vitro comparison of three salbutamol-containing multidose dry powder inhalers: Buventol Easyhaler(R), Inspiryl Turbuhaler(R) and Ventoline Diskus(R). Clin Drug Investig. 2000;20:25–33
  49. Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7:69–73
  50. Newman SP, Morén F, Trofast E, Talaee N, Clarke SW. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm. 1991;74:209–213
  51. Bisgaard H, Klug B, Sumby BS, Burnell PK. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J. 1998;11:1111–1115
  52. Broeders ME, Molema J, Burnell PK, Folgering HT. Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison. J Aerosol Med. 2005;18:74–82
  53. Tarsin WY, Pearson SB, Assi KH, Chrystyn H. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm. 2006;316:131–137
  54. Diamond SA, Chapman KR. The impact of a nationally coordinated pharmacy-based asthma education intervention. Can Respir J. 2001;8:261–265
  55. Janson SL, McGrath KW, Covington JK, Cheng SC, Boushey HA. Individualized asthma self-management improves medication adherence and markers of asthma control. J Allergy Clin Immunol. 2009;123:840–846
  56. Basheti IA, Armour CL, Bosnic-Anticevich SZ, Reddel HK. Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique. Patient Educ Couns. 2008;72:26–33
  57. Newman SP, Talaee N, Clarke SW. Salbutamol aerosol delivery in man with the Rondo-Spacer. Acta Ther. 1991;17:49–50
  58. Mazhar SH, Chrystyn H. Salbutamol relative lung and systemic bioavailability of large and small spacers. J Pharm Pharmacol. 2008;60:1609–1613
  59. Ronmark E, Jogi R, Lindqvist A, et al. Correct use of three powder inhalers: comparison between Diskus, Turbuhaler, and Easyhaler. J Asthma. 2005;42:173–178
  60. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med. 2003;97:181–187

PII: S0954-6111(10)00191-5

doi: 10.1016/j.rmed.2010.04.012

Respiratory Medicine
Volume 104, Issue 9 , Pages 1237-1245 , September 2010

Article Tools

* Image Usage & Resolution